Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05664880 · ClinicalTrials.gov registry record · Early Phase 1

A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis

A Early Phase 1 study of Chronic Pancreatitis, sponsored by Cedars-Sinai Medical Center.

Recruiting
Registry status
Early Phase 1
Development phase
24
Enrollment target
1
Study location

NCT05664880: Recruiting Early Phase 1 study of Chronic Pancreatitis, sponsored by Cedars-Sinai Medical Center.

NCT05664880 is a Early Phase 1 study of Chronic Pancreatitis that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 24 participants, below the 688-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05664880, a Early Phase 1 study of Chronic Pancreatitis, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.

RECRUITING
Registry status
Early Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this pilot study to examine the feasibility and acceptability of paricalcitol in adults with Chronic Pancreatitis (CP).

Primary Outcome

The proposed trial will examine the feasibility of testing the effect of the vitamin D analogue called paricalcitol (also known as Zemplar), on health-related quality of life, imaging, and biomarkers in patients with chronic pancreatitis (CP). Health-related quality of life measurements will be collected via questionnaires to assess overall health, quality of life, and pain. An Acceptability Form will be provided during the last visit to gauge the general acceptability of the intervention. Fea

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Paricalcitol

Study Locations (1)

California

  • Cedars-Sinai Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2023-06-01
Est. Completion 2026-12
Phase Early Phase 1
Cedars-Sinai Medical Center

339 total trials

What NCT05664880 shows while recruiting

NCT05664880 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 688-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Chronic Pancreatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05664880 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05664880 about?

NCT05664880 is a clinical study titled "A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis". The purpose of this pilot study to examine the feasibility and acceptability of paricalcitol in adults with Chronic Pancreatitis (CP).

What is the current status of trial NCT05664880?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2023-06-01. Estimated completion is 2026-12.

What conditions does trial NCT05664880 study?

This clinical trial studies the following conditions: Chronic Pancreatitis.

What interventions are being tested in trial NCT05664880?

The interventions under investigation include: Placebo (DRUG), Paricalcitol (DRUG).

Who is sponsoring clinical trial NCT05664880?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05664880 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pancreatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05664880's enrollment target sits among peer trials

24 36th of 42 higher than 6 of 42 other Chronic Pancreatitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Pancreatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05664880, the US trial registry maintained by the National Library of Medicine. NCT05664880 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.